On Friday, the stock of Rhythm Pharmaceuticals experienced a decline despite receiving FDA approval for its drug, Imcivree, to treat a genetic type of obesity. This approval sets them apart from competitors Lilly and Novo, who have not seen success in this area. The FDA's approval signifies a significant step for Rhythm Pharmaceuticals, even though their stock closed lower by the end of the day.